Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions

被引：0
|
作者：
C. -R Pradeep
A. Zeisel
W. J. Köstler
M. Lauriola
J. Jacob-Hirsch
B. Haibe-Kains
N. Amariglio
N. Ben-Chetrit
A. Emde
I. Solomonov
G. Neufeld
M. Piccart
I. Sagi
C. Sotiriou
G. Rechavi
E. Domany
C. Desmedt
Y. Yarden
机构：
[1] Weizmann Institute of Science,Department of Biological Regulation
[2] Weizmann Institute of Science,Department of Physics of Complex Systems
[3] Tel Aviv University,Department of Pediatric Hemato
[4] Translational Research Unit,Oncology and Functional Genomics, The Chaim Sheba Medical Center and Sackler School of Medicine
[5] Université Libre de Bruxelles,Institut Jules Bordet
[6] Weizmann Institute of Science,Machine Learning Group
[7] Israel Institute of Technology,Department of Structural Biology
[8] The University of Texas MD Anderson Cancer Centre,Cancer Research and Vascular Biology Center, The Bruce Rappaport Faculty of Medicine, Technion
[9] Medical University of Vienna,Department of Systems Biology
来源：
Oncogene | 2024年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1317 / 1317
相关论文
共 50 条
  • [1] Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
    C. -R Pradeep
    A. Zeisel
    W. J. Köstler
    M. Lauriola
    J. Jacob-Hirsch
    B. Haibe-Kains
    N. Amariglio
    N. Ben-Chetrit
    A. Emde
    I. Solomonov
    G. Neufeld
    M. Piccart
    I. Sagi
    C. Sotiriou
    G. Rechavi
    E. Domany
    C. Desmedt
    Y. Yarden
    Oncogene, 2025, 44 (17) : 1207 - 1207
  • [2] Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions
    Pradeep, C-R
    Zeisel, A.
    Koestler, W. J.
    Lauriola, M.
    Jacob-Hirsch, J.
    Haibe-Kains, B.
    Amariglio, N.
    Ben-Chetrit, N.
    Emde, A.
    Solomonov, I.
    Neufeld, G.
    Piccart, M.
    Sagi, I.
    Sotiriou, C.
    Rechavi, G.
    Domany, E.
    Desmedt, C.
    Yarden, Y.
    ONCOGENE, 2012, 31 (31) : 3569 - 3583
  • [3] Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions (vol 31, pg 3569, 2012)
    Pradeep, C. -R
    Zeisel, A.
    Kostler, W. J.
    Lauriola, M.
    Jacob-Hirsch, J.
    Haibe-Kains, B.
    Amariglio, N.
    Ben-Chetrit, N.
    Emde, A.
    Solomonov, I.
    Neufeld, G.
    Piccart, M.
    Sagi, I.
    Sotiriou, C.
    Rechavi, G.
    Domany, E.
    Desmedt, C.
    Yarden, Y.
    ONCOGENE, 2024, 43 (17) : 1317 - 1317
  • [4] Progression and treatment of HER2-positive breast cancer
    April Davoli
    Barbara A. Hocevar
    Thomas L. Brown
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 611 - 623
  • [5] Progression and treatment of HER2-positive breast cancer
    Davoli, April
    Hocevar, Barbara A.
    Brown, Thomas L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 611 - 623
  • [6] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [7] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [8] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [9] Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast cancers
    Koschorke, Ada
    Castagnoli, Lorenzo
    Ghedini, Gaia C.
    Triulzi, Tiziana
    Chiodoni, Claudia
    Canese, Rossella
    Iorio, Egidio
    Iezzi, Manuela
    Nanni, Patrizia
    Tagliabue, Elda
    Pupa, Serenella M.
    CANCER RESEARCH, 2016, 76
  • [10] Correction: Breast cancer: increasing therapy options for HER2-positive early breast cancer
    Nadia Harbeck
    Nature Reviews Clinical Oncology, 2012, 9 (2) : 66 - 66
12345